Elutia Inc. - ELUT STOCK NEWS

Elutia (NASDAQ: ELUT) has announced a new GPO agreement with Advantus Health Partners, marking its seventh GPO agreement since launching EluPro™. The agreement will expand access to EluPro™, the world's first FDA-cleared antibiotic-eluting biologic envelope for cardiac implantable electronic devices and neurostimulators.

EluPro™ combines antibiotics with a natural extracellular matrix that regenerates into patient tissue, addressing post-surgical challenges including infection, migration, and skin erosion. Dr. Kimberly Mulligan, GM and VP of Elutia's Cardiovascular Division, noted that the pilot launch has exceeded expectations, with physicians recognizing the product's unique value in preventing infections.

The partnership with Advantus Health Partners, a healthcare solutions company specializing in supply chain management and cost-savings efficiencies, will help make EluPro™ more widely available to physicians nationwide through their sustainable contracting solutions.

Elutia (Nasdaq: ELUT) has published new preclinical data in Antibiotics journal, demonstrating the effectiveness of its antibiotic-eluting biologic envelope for cardiac implanted electronic devices (CIEDs). The study shows:

The envelope demonstrated complete bacterial eradication across seven different Gram positive and negative organisms, including Staphylococcus aureus, MRSA, and Staphylococcus epidermidis. The technology features rapid initial antibiotic elution followed by gradual release over 14 days.

This research complements the 2024 Garrigos study, validating antimicrobial performance in vivo. The company's product, EluPro, is the first FDA-cleared antibiotic-eluting bioenvelope for CIEDs and neurostimulators, launched commercially in January 2025.

Elutia (NASDAQ: ELUT) reported mixed financial results for Q4 and full year 2024. BioEnvelope product sales showed strong growth, up 18% in Q4 to $2.7M, with same-center sales increasing 65% following EluPro commercialization. The company's newly launched EluPro accounted for over 30% of BioEnvelope sales in Q4.

For full year 2024, BioEnvelope sales rose 5% to $9.9M, while SimpliDerm sales increased 12% to $11.6M. However, overall net sales decreased 1.5% to $24.4M due to declining cardiovascular product sales. The company reported a net loss of $54.1M for 2024, compared to $41.2M in 2023.

EluPro's market penetration has been notable, with 67 approved accounts by year-end and approximately 100 actively ordering accounts. The company strengthened its financial position with a $15M registered direct offering in February 2025.

Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, March 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. Management will be available for discussion during the call, which can be accessed through U.S. (877-407-8029) and International (201-689-8029) dial-in numbers using Conference ID 13751810. A live and archived webcast will be available on the company's investor relations website.

Elutia (NASDAQ: ELUT) has announced a registered direct offering to raise $15.0 million through the sale of 5,520,000 shares of Class A common stock at $2.50 per share and 480,000 prefunded warrants at $2.499 per warrant. The prefunded warrants are immediately exercisable at $0.001 each.

The offering is expected to close around February 4, 2025, with Lake Street Capital Markets acting as the exclusive placement agent. The company plans to use the proceeds for working capital and general corporate purposes. The securities are being offered through an effective shelf registration statement previously filed with the SEC.

Elutia Inc. (ELUT) has announced the full U.S. commercial launch of EluPro™, the first FDA-cleared antibiotic-eluting biomatrix for cardiac implantable electronic devices and neurostimulators. Following a successful pilot program, EluPro has gained strong physician adoption, with submissions to 136 hospital value analysis committees and sales initiated at 70 institutions. The company has established partnerships with four major group purchasing organizations, including Premier and S3P.

The product addresses a significant market opportunity, as over 600,000 cardiac implantable electronic devices are implanted annually in the U.S., with complication rates of 5-7%. EluPro combines rifampin and minocycline antibiotics with a regenerative biomatrix to prevent infections and promote healing. Early results show over 50% increase in envelope orders following VAC approval. The U.S. CIED protection market is valued at $600 million.

Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix products, has announced a significant agreement with Vizient benefiting Southern Strategic Sourcing Partners (S3P). This partnership grants S3P's vast network of 993 acute care facilities access to Elutia’s innovative EluPro™ Antibiotic Eluting BioEnvelope, starting immediately.

EluPro is the first FDA-cleared antibiotic-eluting biologic envelope for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. It combines powerful antibiotics with a natural extracellular matrix that regenerates into the patient’s own tissue, addressing post-surgical challenges such as infection, migration, and skin erosion.

Dr. Randy Mills, CEO of Elutia, highlighted this partnership as a pivotal milestone, marking their second major GPO collaboration ahead of EluPro’s full commercial launch later this month. S3P's network spans over a dozen U.S. states and represents 91 health systems with over $4 billion in annual spend, significantly accelerating Elutia's mission to deliver life-changing technology to more patients.

Elutia (Nasdaq: ELUT) has secured a national group purchasing agreement with Premier, Inc. for Cardiac Rhythm Management Devices, effective November 15, 2024. The agreement enables Premier members to access special pricing for the EluPro™ Antibiotic-Eluting BioEnvelope. EluPro is the first FDA-cleared antibiotic-eluting biologic envelope that combines antibiotics with natural extracellular matrix to provide stability for implantable electronic devices. The technology delivers antibiotics directly to surgical sites and transforms into vascularized tissue, reducing inflammation and simplifying device upgrades. Premier serves two-thirds of U.S. healthcare providers, offering data analytics, supply chain solutions, and consulting services.

Elutia reported Q3 2024 financial results, highlighting the first commercial implant of EluPro, their FDA-cleared antibiotic-eluting biologic envelope. Overall net sales decreased 3.3% to $5.9 million, with SimpliDerm sales growing 19% to $3.1 million. BioEnvelope products sales declined 12% to $2.3 million. The company reported net income of $1.3 million, primarily due to a $12.7 million non-cash warrant revaluation gain. EluPro has been submitted to over 100 hospital VACs, with 36 accounts actively ordering. The company maintains a strong cash position of $25.7 million and is preparing for EluPro's full commercial launch in January 2025.